Imaging DA release in a rat model of L-DOPA-induced dyskinesias: A longitudinal in vivo PET investigation of the antidyskinetic effect of MDMA

NeuroImage

Volumn 63, Issue 1, 2012, Pages 423-433

  Lettfuss, Nadine Y ^a   Fischer, Kristina ^a   Sossi, Vesna ^b   Pichler, Bernd J ^a   von Ameln Mayerhofer, Andreas ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

11C raclopride PET; Dopamine; Dyskinesia; L DOPA; Parkinson's disease

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; BENSERAZIDE; DOPAMINE; LEVODOPA; METHYLPHENIDATE C 11; OXIDOPAMINE; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDYSKINETIC EFFECT; ARTICLE; BRAIN DAMAGE; BRAIN TISSUE; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG ACTIVITY; DRUG EFFICACY; DYSKINESIA; EXPERIMENTAL TEST; IMAGE ANALYSIS; IN VIVO STUDY; LONGITUDINAL STUDY; MALE; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; BRAIN; DOPAMINE; DYSKINESIA, DRUG-INDUCED; LEVODOPA; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84864401446     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2012.06.051     Document Type: Article

References (78)

1. Alexander G.M., Schwartzman R.J., Grothusen J.R., Brainard L., Gordon S.W. Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-dopa treatment. Brain Res. 1993, 625:276-282.
2. Arai R., Karasawa N., Geffard M., Nagatsu I. L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci. Lett. 1995, 195:195-198.
3. Battaglia G., Brooks B.P., Kulsakdinun C., De Souza E.B. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur. J. Pharmacol. 1988, 149:159-163.
4. Baumann M.H., Wang X., Rothman R.B. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 2007, 189:407-424.
5. Baumann M.H., Zolkowska D., Kim I., Scheidweiler K.B., Rothman R.B., Huestis M.A. Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat. Drug Metab. Dispos. 2009, 37:2163-2170.
6. Bishop C., Taylor J.L., Kuhn D.M., Eskow K.L., Park J.Y., Walker P.D. MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation. Eur. J. Neurosci. 2006, 23:2669-2676.
7. Bloom F.E., Algeri S., Groppetti A., Revuelta A., Costa E. Lesions of central norepinephrine terminals with 6-OH-dopamine: biochemistry and fine structure. Science 1969, 166:1284-1286.
8. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:2569-2574.
9. Bymaster F.P., Katner J.S., Nelson D.L., Hemrick-Luecke S.K., Threlkeld P.G., Heiligenstein J.H., Morin S.M., Gehlert D.R., Perry K.W. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002, 27:699-711.
10. Capela J.P., Carmo H., Remiao F., Bastos M.L., Meisel A., Carvalho F. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol. Neurobiol. 2009, 39:210-271.
11. Carson R.E., Channing M.A., Blasberg R.G., Dunn B.B., Cohen R.M., Rice K.C., Herscovitch P. Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J. Cereb. Blood Flow Metab. 1993, 13:24-42.
12. Carta M., Lindgren H.S., Lundblad M., Stancampiano R., Fadda F., Cenci M.A. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J. Neurochem. 2006, 96:1718-1727.
13. Carta M., Carlsson T., Kirik D., Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
14. Carta M., Carlsson T., Munoz A., Kirik D., Bjorklund A. Involvement of the serotonin system in L-dopa-induced dyskinesias. Parkinsonism Relat. Disord. 2008, 14(Suppl. 2):S154-S158.
15. Carta M., Carlsson T., Munoz A., Kirik D., Bjorklund A. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Prog. Brain Res. 2008, 172:465-478.
16. Cenci M.A., Lundblad M. Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr. Protoc. Neurosci. 2007, 41:9.25.1-9.25.23.
17. Cenci M.A., Lee C.S., Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10:2694-2706.
18. Constantinescu C.C., Mukherjee J. Performance evaluation of an Inveon PET preclinical scanner. Phys. Med. Biol. 2009, 54:2885-2899.
19. de la Fuente-Fernandez R., Lu J.Q., Sossi V., Jivan S., Schulzer M., Holden J.E., Lee C.S., Ruth T.J., Calne D.B., Stoessl A.J. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann. Neurol. 2001, 49:298-303.
20. Dehay B., Bezard E. New animal models of Parkinson's disease. Mov. Disord. 2011, 26:1198-1205.
21. Dentresangle C., Veyre L., Le Bars D., Pierre C., Lavenne F., Pollak P., Guerin J., Froment J.C., Brousolle E. Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]dopa and [11C]raclopride PET study. Mov. Disord. 1999, 14:1025-1030.
22. Ding Y.-S., Sugano Y., Fowler J.S., Salata C. Synthesis of the racemate and individual enantiomers of [C-11] methylphenidate for studying presynaptic dopaminergic neuron with positron emission tomography. J. Labelled Compd. Radiopharm. 1994, 34(10):989-997.
23. Doudet D.J., Jivan S., Ruth T.J., Holden J.E. Density and affinity of the dopamine D2 receptors in aged symptomatic and asymptomatic MPTP-treated monkeys: PET studies with [11C]raclopride. Synapse 2002, 44:198-202.
24. Endres C.J., Kolachana B.S., Saunders R.C., Su T., Weinberger D., Breier A., Eckelman W.C., Carson R.E. Kinetic modeling of [11C]raclopride: combined PET-microdialysis studies. J. Cereb. Blood Flow Metab. 1997, 17:932-942.
25. Eskow K.L., Gupta V., Alam S., Park J.Y., Bishop C. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol. Biochem. Behav. 2007, 87:306-314.
26. Fang X., Sugiyama K., Akamine S., Namba H. The stepping test and its learning process in different degrees of unilateral striatal lesions by 6-hydroxydopamine in rats. Neurosci. Res. 2006, 55:403-409.
27. Fischer K., Sossi V., von Ameln-Mayerhofer A., Reischl G., Pichler B.J. In vivo quantification of dopamine transporters in mice with unilateral 6-OHDA lesions using [(11)C]methylphenidate and PET. Neuroimage 2012, 59(3):2413-2422. (Electronic publication ahead of print 2011 Sep 14).
28. Froimowitz M., Gu Y., Dakin L.A., Nagafuji P.M., Kelley C.J., Parrish D., Deschamps J.R., Janowsky A. Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J. Med. Chem. 2007, 50:219-232.
29. Gudelsky G.A., Yamamoto B.K. Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacol. Biochem. Behav. 2008, 90:198-207.
30. Hartvig P., Torstenson R., Tedroff J., Watanabe Y., Fasth K.J., Bjurling P., Langstrom B. Amphetamine effects on dopamine release and synthesis rate studied in the Rhesus monkey brain by positron emission tomography. J. Neural Transm. 1997, 104:329-339.
31. Heffner T.G., Hartman J.A., Seiden L.S. A rapid method for the regional dissection of the rat brain. Pharmacol. Biochem. Behav. 1980, 13:453-456.
32. Hirano S., Asanuma K., Ma Y., Tang C., Feigin A., Dhawan V., Carbon M., Eidelberg D. Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. J. Neurosci. 2008, 28:4201-4209.
33. Hume S.P., Opacka-Juffry J., Myers R., Ahier R.G., Ashworth S., Brooks D.J., Lammertsma A.A. Effect of L-dopa and 6-hydroxydopamine lesioning on [11C]raclopride binding in rat striatum, quantified using PET. Synapse 1995, 21:45-53.
34. Hwang W.J., Yao W.J., Wey S.P., Shen L.H., Ting G. Downregulation of striatal dopamine D2 receptors in advanced Parkinson's disease contributes to the development of motor fluctuation. Eur. Neurol. 2002, 47:113-117.
35. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., Holden J., Houle S., Huang S.-C., Ichise M., Iida H., Ito H., Kimura Y., Koeppe R.A., Knudsen G.M., Knuuti J., Lammertsma A.A., Laruelle M., Logan J., Maguire R.P., Mintun M.A., Morris E.D., Parsey R., Price J.C., Slifstein M., Sossi V., Suhara T., Votaw J.R., Wong D.F., Carson R.E. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 2007, 27:1533-1539.
36. Iravani M.M., Jackson M.J., Kuoppamaki M., Smith L.A., Jenner P. 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J. Neurosci. 2003, 23:9107-9115.
37. Lammertsma A.A., Hume S.P. Simplified reference tissue model for PET receptor studies. Neuroimage 1996, 4:153-158.
38. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab. 2000, 20:423-451.
39. Lauks J., Schmidt W.J. P15 the effect of Mdma and Mde on L-Dopa-induced dyskinesia in parkinsonian rats. Behav. Pharmacol. 2006, 17:545-546.
40. Lebsanft H.B., Mayerhofer A., Kovar K.A., Schmidt W.J. Is the ecstasy-induced ipsilateral rotation in 6-hydroxydopamine unilaterally lesioned rats dopamine independent?. J. Neural Transm. 2003, 110:707-718.
41. Leriche L., Bjorklund T., Breysse N., Besret L., Gregoire M.C., Carlsson T., Dolle F., Mandel R.J., Deglon N., Hantraye P., Kirik D. Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy. J. Neurosci. 2009, 29:1544-1553.
42. Logan J., Fowler J.S., Volkow N.D., Wang G.J., Ding Y.S., Alexoff D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab. 1996, 16:834-840.
43. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2002, 15:120-132.
44. Lundblad M., af Bjerken S., Cenci M.A., Pomerleau F., Gerhardt G.A., Stromberg I. Chronic intermittent L-DOPA treatment induces changes in dopamine release. J. Neurochem. 2009, 108:998-1008.
45. Maeda T., Nagata K., Yoshida Y., Kannari K. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. Brain Res. 2005, 1046:230-233.
46. Mandel R.J., Hartgraves S.L., Severson J.A., Woodward J.J., Wilcox R.E., Randall P.K. A quantitative estimate of the role of striatal D-2 receptor proliferation in dopaminergic behavioral supersensitivity: the contribution of mesolimbic dopamine to the magnitude of 6-OHDA lesion-induced agonist sensitivity in the rat. Behav. Brain Res. 1993, 59:53-64.
47. Margolis J. Ecstasy's Dividend 2001, New York Times.
48. Miller D.W., Abercrombie E.D. Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-treated rats. J. Neurochem. 1999, 72:1516-1522.
49. Miller R., Beninger R.J. On the interpretation of asymmetries of posture and locomotion produced with dopamine agonists in animals with unilateral depletion of striatal dopamine. Prog. Neurobiol. 1991, 36:229-256.
50. Mintun M.A., Raichle M.E., Kilbourn M.R., Wooten G.F., Welch M.J. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann. Neurol. 1984, 15:217-227.
51. Morris E.D., Normandin M.D., Schiffer W.K. Initial comparison of ntPET with microdialysis measurements of methamphetamine-induced dopamine release in rats: support for estimation of dopamine curves from PET data. Mol. Imaging Biol. 2008, 10:67-73.
52. Muller C.P., Carey R.J., Huston J.P., De Souza Silva M.A. Serotonin and psychostimulant addiction: focus on 5-HT1A-receptors. Prog. Neurobiol. 2007, 81:133-178.
53. Munoz A., Carlsson T., Tronci E., Kirik D., Bjorklund A., Carta M. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp. Neurol. 2009, 219:298-307.
54. Nahimi A., Holtzermann M., Landau A.M., Simonsen M., Jakobsen S., Alstrup A.K., Vang K., Moller A., Wegener G., Gjedde A., Doudet D.J. Serotonergic modulation of receptor occupancy in rats treated with l-DOPA after unilateral 6-OHDA lesioning. J. Neurochem. 2012, 120(5):806-817. http://dx.doi.org/10.1111/j.1471-4159.2011.07598.x (Electronic publication ahead of print 2012 Jan 23).
55. Navailles S., Bioulac B., Gross C., De Deurwaerdere P. Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease. Neurobiol. Dis. 2010, 38:136-143.
56. Navailles S., Bioulac B., Gross C., De Deurwaerdere P. Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease. Neurobiol. Dis. 2011, 41:585-590.
57. Nevalainen N., Af Bjerken S., Lundblad M., Gerhardt G.A., Stromberg I. Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia. J. Neurochem. 2011, 118:12-23.
58. Noguchi J., Zhang M.R., Yanamoto K., Nakao R., Suzuki K. In vitro binding of [(11)C]raclopride with ultrahigh specific activity in rat brain determined by homogenate assay and autoradiography. Nucl. Med. Biol. 2008, 35:19-27.
59. Normandin M.D., Morris E.D. Estimating neurotransmitter kinetics with ntPET: a simulation study of temporal precision and effects of biased data. Neuroimage 2008, 39:1162-1179.
60. Ohlin K.E., Sebastianutto I., Adkins C.E., Lundblad C., Lockman P.R., Cenci M.A. Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease. Neuroimage 2012, 61:228-239.
61. Olsson M., Nikkhah G., Bentlage C., Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci. 1995, 15:3863-3875.
62. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, New York.
63. Pehek E.A., Crock R., Yamamoto B.K. Selective subregional dopamine depletions in the rat caudate-putamen following nigrostriatal lesions. Synapse 1992, 10:317-325.
64. Picconi B., Ghiglieri V., Calabresi P. L-3,4-dihydroxyphenylalanine-induced sprouting of serotonin axon terminals: a useful biomarker for dyskinesias?. Ann. Neurol. 2010, 68:578-580.
65. Poewe W., Antonini A., Zijlmans J.C., Burkhard P.R., Vingerhoets F. Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin. Interv. Aging 2010, 5:229-238.
66. Rosa-Neto P., Gjedde A., Olsen A.K., Jensen S.B., Munk O.L., Watanabe H., Cumming P. MDMA-evoked changes in [11C]raclopride and [11C]NMSP binding in living pig brain. Synapse 2004, 53:222-233.
67. Rothman R.B., Baumann M.H., Dersch C.M., Romero D.V., Rice K.C., Carroll F.I., Partilla J.S. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 2001, 39:32-41.
68. Schiffer W.K., Mirrione M.M., Biegon A., Alexoff D.L., Patel V., Dewey S.L. Serial microPET measures of the metabolic reaction to a microdialysis probe implant. J. Neurosci. Methods 2006, 155:272-284.
69. Schmidt W.J., Mayerhofer A., Meyer A., Kovar K.A. Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect?. Neurosci. Lett. 2002, 330:251-254.
70. Sossi V., Dinelle K., Topping G.J., Holden J.E., Doudet D., Schulzer M., Ruth T.J., Stoessl A.J., de la Fuente-Fernandez R. Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study. J. Neurochem. 2009, 109:85-92.
71. Sossi V., Dinelle K., Schulzer M., Mak E., Doudet D.J., de la Fuente-Fernandez R. Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:2364-2370.
72. Sossi V., Dinelle K., Jivan S., Fischer K., Holden J.E., Doudet D. In vivo dopamine transporter imaging in a unilateral 6-hydroxydopamine rat model of parkinson disease using 11C-methylphenidate PET. J. Nucl. Med. 2012, 53:813-822.
73. Sprague J.E., Everman S.L., Nichols D.E. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology 1998, 19:427-441.
74. Tanaka H., Kannari K., Maeda T., Tomiyama M., Suda T., Matsunaga M. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999, 10:631-634.
75. Taylor J.L., Bishop C., Walker P.D. Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat. Pharmacol. Biochem. Behav. 2005, 81:887-893.
76. Tsukada H., Nishiyama S., Kakiuchi T., Ohba H., Sato K., Harada N. Is synaptic dopamine concentration the exclusive factor which alters the in vivo binding of [11C]raclopride?: PET studies combined with microdialysis in conscious monkeys. Brain Res. 1999, 841:160-169.
77. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 1971, 367:69-93.
78. Winkler C., Kirik D., Bjorklund A., Cenci M.A. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 2002, 10:165-186.